Medtronic has initiated a new clinical study in patients implanted with its Resolute Onyx drug-eluting stent (DES) during percutaneous coronary intervention (PCI) procedures.

The Onyx ONE Clear study will assess the use of one-month dual antiplatelet therapy (DAPT) in US and Japanese patients who are at high risk of bleeding.

DAPT is a combination of aspirin and an anti-clotting drug. The study will evaluate its safety, such as any potential cardiac risks, when used with a next-generation DES.

This study is part of the Medtronic Onyx ONE Month DAPT Programme, which also included a prior Onyx ONE Global Study. The DAPT programme is designed to recruit a total of about 2,700 patients across 140 clinical sites globally.